Compare PROF & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PROF | ARMP |
|---|---|---|
| Founded | N/A | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.8M | 199.7M |
| IPO Year | 2017 | 1996 |
| Metric | PROF | ARMP |
|---|---|---|
| Price | $5.76 | $4.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $12.00 | ★ $15.00 |
| AVG Volume (30 Days) | 116.8K | ★ 234.6K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.89 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $16,098,000.00 | N/A |
| Revenue This Year | $92.40 | N/A |
| Revenue Next Year | $64.10 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 50.73 | N/A |
| 52 Week Low | $3.92 | $2.88 |
| 52 Week High | $8.95 | $14.98 |
| Indicator | PROF | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 25.89 | 39.56 |
| Support Level | $4.97 | $3.98 |
| Resistance Level | $6.06 | $5.63 |
| Average True Range (ATR) | 0.35 | 0.57 |
| MACD | -0.12 | -0.06 |
| Stochastic Oscillator | 9.42 | 7.05 |
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.